Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Jakavi“
Suchtreffer
Begriffe & Kennungen
Jakavi · 4.5 · Other interactions to be considered affecting ruxolitinib
Eintrag öffnenJakavi · 4.5 · Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and
Eintrag öffnenJakavi · 4.5 · Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and
Eintrag öffnenJakavi · 4.5 · Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiti
Eintrag öffnenJakavi · 4.5 · Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiti
Eintrag öffnenJakavi · 4.5 · Substances transported by P-glycoprotein or other transporters Ruxolitinib may inhibit P-glycoprotein and brea
Eintrag öffnenJakavi · 4.5 · Substances transported by P-glycoprotein or other transporters Ruxolitinib may inhibit P-glycoprotein and brea
Eintrag öffnenJakavi · 4.5 · When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by
Eintrag öffnenJakavi · 4.5 · When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by
Eintrag öffnenJakavi · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenJakavi · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenJakavi · 4.8 Undesirable effects · 1
Eintrag öffnenJakavi · 4.8 Undesirable effects · 2
Eintrag öffnenJakavi · 4.8 · 12 hypertriglyceridaemia or increased aspartate aminotransferase, nor CTCAE grade 4 increased alanine aminotra
Eintrag öffnenJakavi · 4.8 · 13 Chronic GvHD The most frequently reported adverse drug reactions in REACH3 (adult and adolescent patients)
Eintrag öffnenJakavi · 4.8 · 14 41.4 weeks (range 0.7 to 127.3 weeks). In the pool of paediatric patients ≥2 years of age (10 patients in R
Eintrag öffnenJakavi · 4.8 · 15 Any CTCAEc grade Very common Common a,b Pancytopenia Common Common Bleeding (any bleeding Very common Very
Eintrag öffnenJakavi · 4.8 · 16 Table 7 Frequency category of adverse drug reactions reported in clinical studies in GvHD
Eintrag öffnenJakavi · 4.8 · 17 Hepatobiliary disorders Increased alanine Very common Very common Very common Very common aminotransferase1
Eintrag öffnenJakavi · 4.8 · 18 Thrombocytopenia In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 thrombocytop
Eintrag öffnen